Apoptosis has been implicated in the pathogenesis of marrow failure in MDS and the coexistence of marrow hypercellularity along with blood cytopenias was seen as evidence of extreme cell death of mainly mature cells in the marrow (ineffective hematopoiesis). We investigated apoptosis in 53 patients with MDS, by using single-step DNA extraction and gel electrophoresis and then by separating fresh marrow mononuclear cells in CD34
Introduction
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders occurring mostly in older persons and characterized by blood cytopenias. The FAB classification 1 of these diseases is based mostly on the presence of blast cells in blood and marrow and distinguishes 'good' (refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS)) from 'poor' prognosis (refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEB-t) and chronic myelomonocytic leukemia (CMML)) patients. One of the main determinants of prognosis is the frequent evolution to acute myelogenous leukemia, occurring mostly in 'poor' prognosis patients. 2 Very recently a new widely accepted international scoring system (IPSS) for evaluating prognosis in MDS has been proposed. 3 This system assigns patients in four risk groups by the use of three parameters, namely number of cytopenias, percent of marrow blasts and nature of karyotype abnormalities present.
Apoptosis is a form of cell death with characteristic structural features, which plays an important role in normal embryonic development, elimination of autoreactive lymphocytes and maintenance of steady-state cell numbers in various tissues. A role for apoptosis in bone marrow disorders has been suggested, mainly in situations where a hypercellular marrow is accompanied with pancytopenia, namely diseases Correspondence: NC Zoumbos; Fax: 3 061 993 950 Received 22 September 1998; accepted 7 June 1999 with extensive ineffective hematopoiesis. Several studies already exist and apoptosis has been implicated in patients with beta thalassemia 4 and myelodysplastic syndromes. 5 Raza et al 6 have detected significant apoptosis (Ͼ75% of cells) in marrow biopsies from 50% of MDS patients by using an in situ labelling method and reported that both hematopoietic and stromal cells were participating. On the other hand, Leppeley et al 7 found no evidence of apoptosis in fresh marrow cells, although the phenomenon was induced by incubation. Rajapaksa et al 8 reported significant apoptosis in separated marrow CD34
+ cells from early (refractory anemia) MDS patients, when compared with normal persons and AML patients. The relative participation of CD34
+ and CD34 − marrow cells in the apoptotic process is a very important matter, since the consequences are expected to be entirely different, as the CD34 + population includes all the hematopoietic progenitor cells. Several genes have been implicated in the regulation of apoptosis and among them p53, c-myc and fas are inducers [9] [10] [11] and bcl-2 is an inhibitor of the process. 12, 13 In the above mentioned study of Rajapaksa et al 8 
an increased ratio of expression of c-myc to bcl-2 in CD34
+ cells from MDS patients was found and correlated with the degree of apoptosis.
The goals of our study were: (1) to investigate the incidence of apoptosis in the marrow of patients with MDS; (2) to correlate it with clinical and laboratory parameters and also with the course of the disease; (3) to study the expression of apoptosis-related genes, as bcl-2, fas, p53 and c-myc in MDS marrow cells in relation to the detection of apoptosis; and (4) to specify the relative contribution in the phenomenon of CD34 + and CD34 − marrow cell populations.
Patients and methods

Cell samples
Marrow was aspirated at diagnosis and before the initiation of any treatment from 53 patients with MDS (for diagnostic purposes) and from 12 normal persons, after informed consent. According to FAB classification, nine patients had RA, 10 RARS, 11 RAEB, eight RAEB-t and 15 CMML. No patient had been transfused during the last 20 days before the examination. The main clinical and laboratory characteristics of the patients are shown in Table 1 .
Freshly aspirated heparinized bone marrow cells were suspended in RPMI-1640 medium (ICN-Flow, Costa Mesa, CA, USA). Bone marrow mononuclear cells (MNC) were isolated by Ficoll-Hypaque (ICN-Flow) density gradient centrifugation. Marrow MNC were recovered from the interphase and washed twice in phosphate buffered saline (PBS) (without Ca In four initial experiments we also used the marrow buffy coat. Our cell specimens included progenitor cells, lymphoid 
DNA fragmentation assay
Mononuclear cells were separated by centrifugation on FicollHypaque at 1500 g for 35 min. The cells were then washed twice with PBS, centrifuged at 1000 g for 5 min and the cell pellet was lysed by incubation in 0.5 ml of hypotonic lysis buffer (containing: 5 mm Tris-HCl pH: 8, 10 mm EDTA pH: 8, 0.5% Triton X-100) for 30 min at room temperature. The lysates were centrifuged at 13 000 g for 30 min to separate the fragmented DNA (soluble) from intact chromatin (pellet). Supernatant was precipitated for 16-24 h in 0.5 ml isopropanol (Merck, Darmstadt, Germany) and 0.1 ml NaCI 5 m, at −20°C. The precipitates were pelleted by centrifugation at 10 000 g for 30 min, air dried and dissolved in TE buffer (10 mm Tris HCl pH 7.4) (Sigma, St Louis, MO, USA) and 1 mm EDTA. Ten units RNase A (Sigma) were added to the samples before incubating for 3 h at 37°C. [14] [15] [16] After the addition of an equal volume of loading buffer, the samples were subjected to electrophoresis on a 2% agarose gel for 3 h at 75 V. The agarose gel was stained with ethidium bromide (10 mg/ml) and the resulting DNA fragmentation pattern was visualized and photographed under UV light (UVP, San Gabriel, CA, USA), with Fugi FP-3000B type film.
RNA extraction
RNA was extracted by a guanidinium thiocyanate-phenolchloroform method. 17 
Isolation of CD34
+ hematopoietic cells by highgradient magnetic cell sorting (MACS) 18 
Magnetic labeling procedure:
Light-density bone marrow mononuclear cells were isolated by Ficoll-Hypaque densitygradient centrifugation. The cells were then washed twice in Hank's balanced salt solution (Sigma) and resuspended in 0.3 ml of PBS, 0.5% BSA, 5 mm EDTA per 10 8 cells (Sigma). First, the cells were labeled with 0.1 ml/per 10 8 total cells blocking reagent (human IgG) (CD34 Isolation kit, Miltenyi Biotec, Gladbach, Germany) and 0.1 ml/per 10 8 cells haptenconjugated CD34 antibody (isotype: mouse IgG1). The mixture was incubated for 15 min at 4-12°C. Then the cells were washed with PBS and dialysed against 0.4 ml PBS, 0.5% BSA, 5 mm EDTA. Second, CD34
+ progenitor cells were indirectly magnetically labeled, using 0.1 ml/per 10 8 cells, super-magnetic MACS microbeads recognizing the hapten-conjugated CD34 antibody (incubation for 15 min at 6-12°C). Afterwards, cells were washed twice and resuspended in PBS, 0.5% BSA, 5 mm EDTA (per 10 8 cells).
Magnetic cell sorting:
The assembled column was placed into the MACS magnetic separator. The column (Miltenyi Biotec) was filled with PBS, 0.5% BSA, 5 mm EDTA buffer from the bottom. Then the magnetically stained cells were applied to the column from the top. Three column volumes of buffer were added from the top, the cells were passed and the non-magnetic negative fraction (CD34 − cells) was collected. The column was removed from the separator and placed on a tube; the retained cells (positive fraction: CD34 + cells) were eluted with three column volumes of buffer. The magnetic separation step was repeated (with a new MACS column for rare cells).
In situ cell death detection
In situ nuclear DNA fragmentation was measured according to a method based on the 3Ј-OH end labeling of DNA breaks with modified nucleotides in an enzymatic reaction. 19, 20 Cell samples were fixed in a 2% paraformaldehyde solution (Sigma) (4% in PBS, pH 7.4) for 30 min at room temperature. The slides were rinsed with phosphate buffered saline (PBS, pH: 7.4), incubated in permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 2 min on ice and rinsed with PBS twice. The area around the sample was dried and 0.5 ml TUNEL reaction mixture was added (In Situ Cell Death Detection kit; Boehringer Mannheim, Mannheim, Germany).
The slides were then incubated in a humidified chamber for 60 min at 37°C in the dark and rinsed three times with PBS. Anti-fluorescein AP (alkaline phosphatase) was added on samples and the slides were incubated for 30 min at 37°C. Finally substrate for AP was added on samples and the slides were incubated for 5-20 min at room temperature. Cell sections were analyzed by light microscopy.
Negative and positive controls were included in each experimental set up.
Negative control:
Fixed and permeabilized cells were incubated in 0.05 ml label solution (without terminal transferase) instead of TUNEL reaction mixture.
Positive control:
Fixed and permeabilized cells were incubated with DNase I (1 g/ml) (Boehringer Mannheim) for 10 min at room temperature to induce DNA strand breaks.
Northern blot analysis
The level of expression of c-myc, p53 and ␤-actin genes was determined by Northern blot analysis using 32 P-labeled probes. 21, 22 The following fragments were labeled as probes (Prime a Gene Labeling System; Promega, Madison, WI, USA): SacI fragment DNA (1530 bp) of the human c-myc gene (exon 2); BamH-EcoRI fragment DNA (1985 bp) of the human p53 gene. Total cellular RNA (5-10 g) was electrophoresed on a 1.2% agarose/5% formaldehyde gel and transferred on to a nitrocellulose membrane (Zetaprobe; BioRad, Hercules, CA, USA). Prehybridization and hybridization of the RNA was carried out in high stringency conditions. The membrane was prehybridized for 2 h at 42°C. Random-primed 32 P labeled probes were heat-denatured, cooled, added to the buffer and hybridized for 18-24 h at 42°C. The hybridized filters were washed twice in 2 × SSPE and 0.3% SDS (Sigma) for 15 min at 42°C, twice in 1 × SSPE and 0.5% SDS for 15 min at 42°C and twice in 0.3 × SSPE and 1% SDS for 15 min at 50°C. The blots were exposed to Kodak X-OMAT AR film (Eastman Kodak Company, Rochester, NY, USA) at −70°C for autoradiography and developed for an appropriate period (24-48 h).
RT-PCR amplification
One microgram of total cellular RNA was reverse transcribed into cDNA using 200 U superscript RT (Gibco BRL, Maryland, USA) and 50 ng random oligonucleotide mix (Promega) for 1 h at 37°C, in 25 mm Tris-HCl pH: 8.3, 37.5 mm KCl, 5 mm MgCl 2 , 0.5 mm of each dNTP (Promega), 5 g bovine serum albumin and 10 U RNA inhibitor (Gibco BRL) at a final volume of 30 l. 5 l of cDNA were used in each PCR reaction which was composed as follows: 20 mm Tris-HCl pH 8.4, 50 mm KCl, 1.5 mm MgCl 2 , 0.5 m of each primer, 250 m of each dNTP and 2.5 U Taq polymerase (Gibco BRL) in a final volume of 50 l. cDNA was amplified for 35 cycles at the following conditions: 1 min at temperatures between 52°C and 64°C, depending on the T m of the pair of primers used and 1 min at 72°C for elongation followed by a 5-min extension at 72°C after the last cycle in a Perkin Elmer Cetus (Gene Amp PCR system 9600) (Perkin-Elmer Corporation, Norwalk, CT, USA).
Amplified DNA fragments were separated on a 2% agarose gel and photographed after ethidium bromide staining. PCR amplification of cDNA using ␤ 2 -microglobulin specific primers was used as a control for cDNA quality. For all genes, cDNA synthesis and PCR analysis were performed at least twice. Each experiment included a negative control for cDNA synthesis (cDNA synthesis reagents without RNA), a PCR negative control (PCR reagents without cDNA) and a PCR positive control. Primer sequences were as follows: 5Ј-GAG ACT CAG AAC TTG GAA GGC-3Ј and 5Ј-TGA CTT AGT GTC ATG ACT CCA G-3Ј for amplification of Fas mRNA, 5Ј-TCC AGC CAG CTG CAC CTG AC-3Ј and 5Ј-TTG ACG CTC TCC ACA CAC ATG A-3Ј for amplification of bcl-2 mRNA and 5Ј-CCC CCA CTG AAA AAG ATG AG-3Ј and 5Ј-TCA CTC AAT CCA AAT GCG GC-3Ј for amplification of ␤ 2 -microglobulin mRNA.
Phosphorimager densitometry
Quantitative analysis was performed on photographs of ethidium bromide gels (scanned at 300 dpi with a HP 6100 scanner) using the Image QuaNT image analysis software (Molecular Dynamics, Sunnyvale, CA, USA).
Statistical analysis
Kaplan-Meier curves were used to estimate survival and probability to transformation. 23 Log-rank test was used to compare survival curves. Univariate and multivariate analysis for prognostic factors on survival and probability to transformation were calculated using the Cox model. 23 Fischer's exact test was used to compare differences between groups, whereas Mann-Whitney test was used to compare the mean values for categorical variables. All analyses were done using NCSS Statistical Software (North Kaysville, UT, USA). Table 1 shows the main clinical characteristics of patients studied and Table 2 shows the incidence of apoptosis, as detected by using single-step DNA extraction and gel electrophoresis. Eighteen out of 53 marrow samples (34%) from MDS patients showed evidence of apoptosis. Among the various Figure 1 shows the characteristic pattern of fragmented DNA in positive specimens from patients along with negative ones.
Results
Incidence of apoptosis in fresh marrow cells from MDS patients
Clinical and laboratory correlations
Patients with marrow samples positive for apoptosis had similar age, hemoglobin level, white blood cell and platelet count and almost similar red blood cell annual transfusion requirements with those without apoptosis (Table 3 ). However, they had increased marrow cellularity (80.8 ± 5.1 vs 66.6 ± 3.8%, P = 0.036) and longer overall survival (43.6 ± 8.3 vs 22.7 ± 3.9 months, P = 0.0155). Thirteen out of 35 patients not exhibiting apoptosis (37%) were transformed to acute myeloid leukemia (AML) vs five out of 18 (28%) manifesting apoptosis (P = 0.1). Marrow from eight patients, which were found positive for apoptosis, was tested two or more times at various time intervals. In four patients with stable disease prominent marrow cells apoptosis was found during all examinations. In contrast, in the remaining patients, examined for the second time during leukemic transformation, the marrow apoptotic pattern was no longer evident.
When we compared separately the positive and negative for apoptosis patients of the group of RA and RARS, we found an extremely significant difference only in the bone marrow cellularity (91.6 ± 2.6 positive vs 58 ± 5.17% negative samples, P = 0.0001), while no difference was found concerning the hemoglobin level, the white blood cell and platelet count, the transfusion requirements and overall survival.
In the 'poor' prognosis group, the comparison of the above parameters concerning patients with RAEB and RAEB-t did not reveal any difference, while in patients with CMML significant difference in survival was found in favor of those with apoptosis (87.3 ± 25 vs 11.4 ± 2.5 months, P = 0.0003) (Figure 2 ).
Median survival for alive patients without apoptosis was 30 months (range 7-90), whereas the median survival for alive patients with apoptosis was 66 months (range 44-123) (P = Figure 1 Electrophoretic analysis of DNA degradation. Genomic DNA from two normal individuals: Nos 1, 4 (lanes 8, 9) and seven MDS patients: Nos 6, 7, 11, 20, 37, 18, 41 (lanes 1-7) was isolated as described in Materials and methods and electrophoresed on a 2% agarose gel, containing 0.1 g/ml ethidium bromide. Lanes 1, 6, 7, show the characteristic apoptotic pattern and lanes 2, 3, 4, 5, 8 and 9 are negative. 
Figure 2
Kaplan-Meier estimation of probability of survival for patients with CMML, with and without apoptosis.
0.001).
The corresponding values for the evolution to AML was 12 months (range 1-90) for patients without apoptosis and 41 months (2-123) (P = 0.082) for patients with apoptosis. The overall probability of survival was statistically significantly higher for patients without apoptosis as compared to patients with apoptosis (log rank test 0.03), and this was true for high risk patients (RAEB and RAEB-t, P = 0.01) but not for low risk patients (RA and RARS, P = 0.6). There was no statistically significant difference concerning the evolution to AML for the whole cohort of patients (apo− vs apo+, P = 0.1), neither for low (apo− vs apo+, P = 0.75) nor for high risk group (apo− vs apo+, P = 0.27).
Prognostic factors on survival
Factors affecting statistically significantly the overall survival in univariate analysis were found: FAB classification (P = 0.02), apoptosis (P = 0.045), the International Prognostic Scoring System (IPSS) (P = 0.004), and bone marrow percentage of blasts (P = 0.002), whereas white blood cells at diagnosis (P = 0.05) and age (P = 0.05) were of borderline significance. In multivariate analysis including only factors found to be significant in univariate analysis, factors which remained significant were: age (P = 0.003), white blood cells at diagnosis (P = 0.01) and bone marrow percentage of blasts (P = 0.02).
Prognostic factors on transformation to acute leukemia
Factors statistically significant for transformation to acute leukemia in univariate analysis were: the IPSS (P = 0.001) and bone marrow percentage of blasts (P Ͻ 0.0001). In multivariate analysis including only those factors found to be significant in univariate analysis, the factor remaining significant was only the bone marrow percentage of blasts (P Ͻ 0.001).
Expression of apoptosis-related genes in total marrow cells
Expression of p53 and c-myc genes was investigated with Northern blot in total marrow cells from 15 patients with MDS. As it is shown in Table 4 , c-myc was expressed in 6/15 (40%), while p53 in 9/15 (60%) of patients studied. Expression of both genes was found in five, of neither gene in five and of only one gene in five cases (p53 alone in four and c-myc alone in one). In cases with expression of at least one of the above genes, apoptosis was not detected and in contrast when expression of both genes was absent, apoptosis was evident. 
Figure 3
Northern blot analysis of c-myc, p53 and ␤-actin genes. RNA from each sample was transferred to a nitrocellulose membrane after electrophoresis and hybridized to probes specific for c-myc, p53 and ␤-actin, as described in Materials and methods. 
In situ detection of apoptosis in separated populations of CD34
+ and CD34 − marrow cells
In order to further investigate the significance of apoptosis in patients with MDS, we separated freshly aspirated marrow mononuclear cells from 12 patients and four healthy persons in CD34 + and CD34 − populations, by using a magnetic cell sorter (MACS) and then we used an in situ cell death detection kit (TUNEL technique). This procedure augments the sensitivity and permits detection of apoptosis in single cells. In three patients with RA and RARS, apoptosis was evident in the total marrow cell population and in both separated cell populations, in percentages ranging from 6 to 49%. In all other patients (two with RAEB, three with RAEB-t and two with CMML) apoptosis in total marrow and in CD34 − cells was detected only in a few cells, although a large proportion (9-94%) of CD34 + cells were apoptotic (Table 5 ). Apoptotic cells were almost absent from total and separated CD34 + and CD34
− normal marrow cells tested. Figure 4 shows representative positive and negative for apoptosis samples.
Expression of Bcl-2 and Fas in CD34
+ cells
The expression of bcl-2 and fas was investigated in isolated populations of CD34 + and CD34 − marrow cells from MDS patients by using a semi-quantitative RT-PCR ( Figure 5 ). Analysis of bcl-2 mRNA levels ( Table 6 ) leads to the following remarks: (1) very low levels (р0.1) were always correlated with detection of apoptosis; (2) high levels (Ͼ1.0) were found in cases where apoptosis was not evident; (3) 
6). RT-PCR did not detect any expression of fas in CD34
+ cells freshly isolated from BM, while Fas expression in CD34
− cells, was not correlated with the degree of apoptosis detected (by DNA fragmentation, or by TUNEL analysis). It is probable that the expression of other genes is also of importance, as the study of Rajapaksa et al 8 has shown, namely that the balance between pro-apoptotic and anti-apoptotic proteins may play a significant role.
Discussion
The data presented above suggest apoptosis as a probable contributing mechanism in the pathogenesis of marrow failure in MDS. We detected apoptosis in 34% of MDS patients' fresh marrow mononuclear cells and this is in accordance with data from other investigators; Raza et al, 6 by using a different material (marrow biopsies) detected apoptosis in 40% of patients and Cortelezzi et al 24 by using dual-color direct immunofluorescence found that 38.7% of MDS patients had increased apoptosis. On the other hand, Lepelley et al 7 reported absence of apoptosis in fresh marrow cells from MDS patients and enhancement of the phenomenon after incubation. We should stress that there are many differences between the above studies, concerning the extension of the phenomenon and the types of cells involved. Raza et al 6 detected apoptosis in more than 50% of total marrow cells and the process was also evident in stromal cells. In our series, when the in situ detection method was applied, in 'good' prognosis MDS patients with evidence of apoptosis, this concerned both CD34
+ and CD34 − cells, but in 'poor' prognosis or late MDS it was almost exclusively detected in a high proportion of CD34 + cells. Rajapaksa et al 8 in a study reported more apoptosis in CD34
+ than in CD34 − cells in MDS marrow and the same conclusion is reached by Peddie et al 25 by using a sensitive DNA strand break detection assay.
Several methodological issues are emerging if one tries to explain the above discrepancies. First of all the difference in the material used (biopsy vs fresh marrow) or in the involvement of an incubation step in the different studies may provide some explanations for the conflicting data. Second, Alvi et al 26 have reported that the presence of a high molecular weight fragmented DNA in MDS patients, could not be detected by the usual single-step extraction of DNA that we and others are routinely using. This problem though can be bypassed by the use of the in situ TUNEL technique, which labels both high and low molecular weight fragmented DNA. Another argument could be that we are detecting more apoptosis in separated CD34 + cells, because these cells are more factor-dependent than the more mature cells, but the absence of the phenomenon in normal separated CD34 + marrow cells is in favor of a biological difference between normal and MDS CD34 + cells. A significant advantage of the TUNEL technique is the ability to detect apoptosis in small numbers of cells. Detection of 'apoptotic pattern' of separated CD34 + cells in gels is very difficult, due to the usually very small number of these cells after magnetic separation. The low number of CD34 + cells in the samples and the sensitivity of the in situ method explain some of our data, where we detected apoptosis with the 
TUNEL technique in separated CD34
+ cells, although no apoptotic pattern was detected in the gel derived from total marrow DNA.
Our finding that apoptosis was evident only in cases where p53 and c-myc expression was not detected in total marrow cells is of potential interest, although very difficult to explain. There are previous reports proposing independence of the apoptotic mechanism from p53, when factor withdrawal was the prevailing effector, 27, 28 but another explanation could be that other genes' function is more important for the regulation of apoptosis in MDS marrow. By using a semi-quantitative RT-PCR technique in isolated CD34
+ and CD34 − marrow cells, we found that the expression of bcl-2 was very low in CD34 + marrow cells from certain cases and this was correlated with high degrees of apoptosis.
The findings of this report are in accordance with the in vitro short-term culture data in MDS marrow, where a very low plating efficiency is the rule 29 and could signify a defective maintenance of hematopoietic progenitors in MDS marrow, which is contributing to the marrow failure. We have also found that by adding a combination of hematopoietic growth factors, a significant increase in the plating efficiency of MDS marrow and blood progenitors can be achieved, presumably by an anti-apoptotic mechanism (manuscript in preparation).
The finding that patients with evident marrow apoptosis showed increased survival, when compared with patients without apoptosis is of more significance when analyzed in the same subgroup of patients and it seems that this is true concerning CMML, where a significant difference in the survival between patients with and without apoptosis was found. Patients with detectable marrow apoptosis had also shown a longer interval to evolution to AML and this seems to be irrelevant to the FAB classification, offering perhaps an independent risk factor for MDS patients. The reason for this 'protective' effect of apoptosis in MDS is not clear, but it is known that leukemogenesis is more probable when a damage of DNA leads in proliferation and not in apoptosis of involved cells. The presence of apoptosis may thus be a sign of an earlier stage in the leukemogenic process. In favor of this hypothesis is also our finding that apoptosis was no longer evident in four patients tested again in the phase of leukemic transformation (although was present in repetitive examinations of stable, non-transformed patients), and also previous reports that apoptosis is a rare phenomenon in marrow from patients with AML. 30 Many crucial questions remain to be answered concerning the significance of apoptosis in the marrow failure of MDS and one of them is certainly the relative involvement of normal and myelodysplastic progenitors in the process. We must also realise that the well known heterogeneity of MDS can be better explained by a non-uniform contribution of the apoptotic process in the death of particular cell types, than by an absolutely unifying concept.
Based on the above data, but also on previous reports, we can formulate the following hypothesis: apoptosis, when detected in early MDS concerns both CD34 + and CD34 − cells. Hematopoiesis at this stage is not entirely clonal and a significant number of normal progenitors is contributing along with the dysplastic ones. In more advanced cases, like RAEB and RAEB-t far fewer normal progenitor cells are surviving to give birth to more mature cells; the non-apoptotic dysplastic cells have at this point a survival advantage and their progeny are almost exclusively populating the marrow. Apoptosis is detected now almost exclusively in CD34
+ cells, which comprise a very small proportion of total marrow cells and for this reason is not easily detected with the usual methods combining single step DNA extraction and gel electrophoresis. When reversion to frank AML occurs, the leukemic clone is now entirely repopulating the marrow, very often with CD34
+ leukemic cells and at the same time almost totally suppressing normal hematopoiesis. At this stage of the disease apoptosis is not detected at all. All these changes are presumably caused by differential expression of oncoproteins, as the study of Rajapaksa et al 8 has shown, with a 'pro-apoptosis' high ratio of c-myc/bcl-2 in early MDS and a lower 'anti-apoptosis' ratio in more advanced MDS and AML. In the light of the above data, the combination of a hypercellular marrow and blood pancytopenia in advanced cases of MDS could be better explained not by an increased apoptosis of precursors in the marrow, but by an increased residence in the marrow and in fact resistance to apoptosis, of the cells of the surviving myelodysplastic clone.
